Genentech gets gluey, paying $47M upfront to Orionis for degrader discovery deal - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
In its second deal announced Wednesday morning, Roche’s Genentech is signing up with Orionis Biosciences for a molecular glue partnership in cancer and neurodegeneration. Genentech will pay Orionis $47 million upfront, and it’s promised over $2 billion in pot…